HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo.

Abstract
Death receptor targeting has emerged as one of the promising novel approaches of cancer therapy. The activation of one such prototypic death receptor, CD95 (Fas/APO-1), has remained controversial because CD95 agonistic molecules have exhibited either too strong toxicity or too little activity. The natural CD95 ligand (CD95L) is a cytokine, which needs to trimerize to mediate a cell death signal. Mega-Fas-Ligand, now referred to as APO010, is a synthetic hexameric CD95 agonist that exhibits strong antitumor activity in various tumor models. Here, we studied the effects of APO010 in human glioma models in vitro and in vivo. Compared with a cross-linked soluble CD95L or a CD95-agonistic antibody, APO010 exhibited superior activity in glioma cell lines expressing CD95 and triggered caspase-dependent cell death. APO010 reduced glioma cell viability in synergy when combined with temozolomide. The locoregional administration of APO010 induced glioma cell death in vivo and prolonged the survival of tumor-bearing mice. A further exploration of APO010 as a novel antiglioma agent is warranted.
AuthorsGünter Eisele, Patrick Roth, Kathy Hasenbach, Steffen Aulwurm, Fabian Wolpert, Ghazaleh Tabatabai, Wolfgang Wick, Michael Weller
JournalNeuro-oncology (Neuro Oncol) Vol. 13 Issue 2 Pg. 155-64 (Feb 2011) ISSN: 1523-5866 [Electronic] England
PMID21183510 (Publication Type: Journal Article)
Chemical References
  • Fas Ligand Protein
  • Mega-Fas-ligand
  • Recombinant Fusion Proteins
  • fas Receptor
Topics
  • Animals
  • Apoptosis (drug effects)
  • Blotting, Western
  • Brain Neoplasms (metabolism, pathology, prevention & control)
  • Cell Proliferation (drug effects)
  • Fas Ligand Protein (immunology, pharmacology)
  • Flow Cytometry
  • Glioma (metabolism, pathology, prevention & control)
  • Humans
  • Immunoenzyme Techniques
  • In Vitro Techniques
  • Mice
  • Recombinant Fusion Proteins (immunology, pharmacology)
  • Tumor Cells, Cultured
  • fas Receptor (agonists, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: